Mavacamten for hypertrophic obstructive cardiomyopathy.
Publication
, Journal Article
Quintana, E; Bajona, P; Myers, PO
Published in: Lancet
January 30, 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
January 30, 2021
Volume
397
Issue
10272
Start / End Page
369
Location
England
Related Subject Headings
- Uracil
- Humans
- General & Internal Medicine
- Double-Blind Method
- Cardiomyopathy, Hypertrophic
- Benzylamines
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Quintana, E., Bajona, P., & Myers, P. O. (2021). Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet, 397(10272), 369. https://doi.org/10.1016/S0140-6736(20)32384-9
Quintana, Eduard, Pietro Bajona, and Patrick O. Myers. “Mavacamten for hypertrophic obstructive cardiomyopathy.” Lancet 397, no. 10272 (January 30, 2021): 369. https://doi.org/10.1016/S0140-6736(20)32384-9.
Quintana E, Bajona P, Myers PO. Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet. 2021 Jan 30;397(10272):369.
Quintana, Eduard, et al. “Mavacamten for hypertrophic obstructive cardiomyopathy.” Lancet, vol. 397, no. 10272, Jan. 2021, p. 369. Pubmed, doi:10.1016/S0140-6736(20)32384-9.
Quintana E, Bajona P, Myers PO. Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet. 2021 Jan 30;397(10272):369.
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
January 30, 2021
Volume
397
Issue
10272
Start / End Page
369
Location
England
Related Subject Headings
- Uracil
- Humans
- General & Internal Medicine
- Double-Blind Method
- Cardiomyopathy, Hypertrophic
- Benzylamines
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences